Ryan Gentzler, MD
Dr. Ryan Gentzler is a medical oncologist specializing in thoracic malignancies at UVA Health and the UVA Comprehensive Cancer Center in Charlottesville, Virginia. His clinical practice is dedicated to treating patients with lung cancer, malignant pleural mesothelioma, non-small cell lung cancer, small cell lung cancer, and thymus cancers. He is particularly interested in the use of novel therapies, cancer immunology, and targeted therapy to treat these challenging conditions. In addition to improving his patients’ outcomes, Dr. Gentzler’s goal is to contribute meaningful research that leads to improvements in the curability, survival, and quality of life of patients with lung cancer.[1]
Education and Career
Dr. Gentzler earned a Bachelor of Science degree from Davidson College, then attended the Temple University Lewis Katz School of Medicine. His internship and residency in Internal Medicine were completed at Thomas Jefferson University Hospital in Philadelphia, then went on to complete his Hematology/Oncology fellowship at Northwestern University. He also earned a Master of Science degree in Pharmacology from the National Institutes of Health K30 training program in human investigation at Thomas Jefferson University.[1]
Professional Memberships and Activities
Dr. Gentzler is a member of the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer (IASLC). He is also an active member of the ECOG-ACRIN (Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network) cooperative group.[1]
Research
Dr. Gentzler is actively involved in clinical trials investigating novel drug development, cancer immunology, and targeted therapy for patients with lung cancer and other thoracic malignancies. He has been a co-principal Investigator on the National Cancer Institute (NCI) UM1 grant that funds the Johns Hopkins University LAO phase I/II consortium for the NCI Experimental Therapeutic Clinical Trials Network (ETCTN), co-chair of the Thoracic Clinical Trial Working Group for the Hoosier Cancer Research Network (HCRN).[1]
Dr. Gentzler’s recent publications include:[2]
- Devitt M, Hall R, Gentzler RD, Peripheral Blood Cell-Free DNA to Monitor Mutational Response in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer., 2017; International journal of radiation oncology, biology, physics. 98(1) 250. PMID: 28587042
- Gentzler RD, Mehindra NA, Hanna N, Chae YK, Jalal SI, Hall R, Villaflor VM, Reckamp KL, Koczywas M, Sullivan D, Wood L, Patel JD, Carboplatin/nab-Paclitaxel and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 1 Results., 2017; International journal of radiation oncology, biology, physics. 98(1) 236. PMID: 28587008
- Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L, Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomized, phase 2 cohort of the open-label KEYNOTE-021 study., 2016; The Lancet. Oncology. 17(11) 1497-1508. PMID: 27745820
- Gentzler R, Hall R, Kunk PR, Gaughan E, Dillon P, Slingluff CL, Rahma OE, Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors., 2016; Immunotherapy. 8(5) 583-600. PMID: 27140411
- Hall RD, Le TM, Haggstrom DE, Gentzler RD, Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC)., 2015; Translational lung cancer research. 4(5) 515-23. PMID: 26629420 | PMCID: PMC4630516
- Gentzler RD, Johnson ML, Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancer., 2015; The oncologist. 20(3) 299-306. PMID: 25660158 | PMCID: PMC4350796
